Kieran Gostin is a Partner at Wilkinson Stekloff. He has represented the government and private clients in high-profile matters for the past decade. Recently, he has represented clients in several major class actions, including obtaining a complete defense verdict in a rare trial of a major consumer class action. Prior to those representations, he spent several years representing Bayer in products liability litigation, including being a member of four trial teams that obtained defense judgments for our client.
In recognition of these successful outcomes, Kieran has received “rising star” awards from the National Law Journal, Benchmark Litigation, and Law360.
Before joining the firm, Kieran was a trial attorney in the Federal Programs Branch of the U.S. Department of Justice, where he was the lead attorney in matters challenging the legality of executive agency action, including cases involving challenges to federal healthcare and national security programs.
- Undergraduate: Georgetown University, B.A., cum laude.
- Masters: London School of Economics and Political Science, M.Sc., Pass with Merit.
- Law: Harvard Law School, J.D., cum laude.
- Judge Thomas L. Ambro, United States Court of Appeals for the Third Circuit
- Judge Shira A. Scheindlin, United States District Court for the Southern District of New York
- Member of trial team that won complete defense verdicts in first two bellwether trials in In re: Xarelto (Rivaroxban) Products Liability Litigation, a nationwide federal MDL proceeding involving over 20,000 lawsuits related to the blood-thinner Xarelto.
- Member of trial team that won JNOV in Hartman v. Janssen, the first state-court bellwether trial involving Xarelto in Philadelphia’s Court of Common Pleas.
- Represented Forest Laboratories in In re Namenda Direct Purchaser Antitrust Litigation, a certified antitrust class action in the Southern District of New York involving a groundbreaking treatment for dementia in Alzheimer’s patients. Plaintiffs claimed that Forest made an anticompetitive “reverse payment” to settle a generic drug manufacturer’s challenge to Namenda, and that Forest unlawfully tried to effectuate a “hard switch” between a twice-daily and once-daily version of Namenda. Plaintiffs claimed approximately $21 billion in trebled damages; the case settled the night before trial for less than 5% of that amount.
- Member of trial team in a multi-state class action tried in February 2019 that accused Bayer Corporation of using misleading claims to market One A Day multivitamins. Kieran was responsible for arguing legal issues at the trial, as well as cross examining one of the class representatives. The jury returned a complete defense verdict in less than two hours.
- Lead attorney for federal government in successful defense of national security program related to the sharing of information about suspicious activities among state, local, and federal law enforcement.
- Lead attorney for federal government in challenge to constitutionality of the Navy Chaplain Corps’ decision not to commission an officer candidate endorsed by a humanist organization. The Court dismissed all but one of the candidate’s First Amendment, RFRA, and other claims, and the government subsequently entered into a favorable settlement to resolve the dispute.